501 件 ・ 関連度順
概要と使いどころ
Run TAO Data Services KPI analysis for object detection, comparing inference annotations against ground truth to compute per-class TP/FP/FN/TN, precision, recall, accuracy, and AP at a fixed IoU. Use when an object detection workflow needs per-class mAP reported after inference, or when the user asks to "run KPI analyze", "compute detection mAP", or "score my OD predictions against ground truth".
日本語の概要は準備中です。原文の説明を表示しています。
Use Boltz2 NIM for biomolecular structure prediction and binding affinity. Invoke for Boltz2, protein structures, protein-ligand/DNA/RNA complexes, SMILES or CCD ligands, pIC50/IC50 affinity scoring, mmCIF output, hosted NVIDIA API calls, or local Docker deployment.
日本語の概要は準備中です。原文の説明を表示しています。
NOTE: molecule and target inputs and your NGC_API_KEY are transmitted to external NVIDIA-hosted API endpoints on every call. Use local NIM containers for confidential or proprietary data. Run a complete computational drug discovery pipeline using NVIDIA BioNeMo NIMs: generate drug-like molecules with GenMol, dock them to a protein target with DiffDock, then predict binding affinity with Boltz2. Use this skill whenever the user wants to generate and screen small molecule drug candidates, perform hit discovery, optimize leads against a protein target, or do virtual screening combining molecule generation, docking, and affinity prediction. Triggers on: drug discovery pipeline, hit discovery, lead optimization, virtual screening, molecule generation, molecular docking, binding affinity, GenMol, DiffDock, Boltz2, SMILES, SAFE notation, NIM microservice. This is a multi-step pipeline composing three BioNeMo NIMs.
日本語の概要は準備中です。原文の説明を表示しています。
Run predictions with a finetuned KERMT checkpoint on a SMILES-only CSV. The skill validates that the input ckpt has task FFN heads (refuses pretrain ckpts with a redirect to kermt-finetune), validates the CSV, prepares the data (clean + rdkit_2d features), then launches main.py predict inside the kermt container (blocking, minutes-scale).
日本語の概要は準備中です。原文の説明を表示しています。
Combined verification — recite (description quality via cold-read prediction) + validate (schema compliance) + review (health checks). Use as a quality gate after creating notes or as periodic maintenance. Triggers on "/verify", "/verify [note]", "verify note quality", "check note health".
日本語の概要は準備中です。原文の説明を表示しています。
Market prediction skill using Kronos. Use when user needs finance market time-series forecasting or news-aware finance market adjustments.
日本語の概要は準備中です。原文の説明を表示しています。
Identify tumor neoantigens from somatic mutations using pVACtools for personalized cancer immunotherapy. Predict mutant peptides that bind patient HLA and may elicit T-cell responses. Use when identifying vaccine targets or checkpoint inhibitor response biomarkers from tumor sequencing data.
日本語の概要は準備中です。原文の説明を表示しています。
Predict metagenome functional content from 16S rRNA marker gene data using PICRUSt2. Infer KEGG, MetaCyc, and EC abundances from ASV tables. Use when functional profiling is needed from 16S data without shotgun metagenomics sequencing.
日本語の概要は準備中です。原文の説明を表示しています。
Predict B-cell and T-cell epitopes using BepiPred, IEDB tools, and structure-based methods for vaccine and antibody design. Identify immunogenic regions in antigens. Use when designing vaccines, mapping antibody binding sites, or predicting immunogenic peptides.
日本語の概要は準備中です。原文の説明を表示しています。
Predict peptide-MHC class I and II binding affinity using MHCflurry and NetMHCpan neural network models. Identify potential T-cell epitopes from protein sequences. Use when predicting MHC binding for vaccine design or neoantigen identification.
日本語の概要は準備中です。原文の説明を表示しています。
Predict CRISPR off-target sites using Cas-OFFinder and CFD scoring algorithms. Identify potential unintended cleavage sites genome-wide and assess guide specificity. Use when evaluating guide RNA specificity or selecting guides with minimal off-target risk.
日本語の概要は準備中です。原文の説明を表示しています。
Design guides for cytosine and adenine base editing using editing window optimization and BE-Hive outcome prediction. Select optimal positions for C-to-T or A-to-G conversions without double-strand breaks. Use when designing base editor experiments for precise nucleotide changes.
日本語の概要は準備中です。原文の説明を表示しています。
Predicts ADMET properties using ADMETlab 3.0 API or DeepChem models. Estimates bioavailability, CYP inhibition, hERG liability, and 119 toxicity endpoints with uncertainty quantification. Filters for PAINS and other structural alerts. Use when filtering compounds for drug-likeness or prioritizing leads by predicted safety.
日本語の概要は準備中です。原文の説明を表示しています。
Call HLA alleles from NGS data using OptiType, HLA-HD, or arcasHLA for immunogenomics applications. Use when determining HLA genotype for transplant matching, neoantigen prediction, or pharmacogenomic screening.
日本語の概要は準備中です。原文の説明を表示しています。
Formulate evidence-bounded scientific questions, candidate hypotheses, rival explanations, causal or associational claims, discriminating predictions, measurements, and preregistration-ready analysis plans. Use when turning observations or preliminary findings into transparent, testable research plans without treating hypotheses as facts.
日本語の概要は準備中です。原文の説明を表示しています。
Use when drafting patient discharge summaries, creating personalized discharge instructions, simulating post-discharge outcomes, reducing hospital readmissions, or optimizing care transitions. Generates AI-enhanced discharge documentation with digital twin predictions for improved patient safety.
日本語の概要は準備中です。原文の説明を表示しています。
Generates complete reference-grounded single-drug adverse-effect network-pharmacology research designs from a user-provided drug, adverse event, and desired evidence depth. Always use this skill when a user wants to design, plan, or upgrade a conventional network-pharmacology study centered on one fixed drug and one fixed adverse-effect endpoint, using drug-target prediction, adverse-event target collection, overlap analysis, PPI hub prioritization, enrichment interpretation, molecular docking, and optional orthogonal transcriptomic or literature validation. Covers five study patterns (canonical hub-first, cardiotoxicity or electrophysiology-oriented, immune-inflammatory adverse effect, organ-toxicity pathway context, translational validation) and always outputs four workload configs (Lite / Standard / Advanced / Publication+) with a recommended primary plan, dependency/evidence map, step-by-step workflow, figure plan, validation strategy, minimal executable version, publication upgrade path, verified-reference pack, and self-critical risk review.
日本語の概要は準備中です。原文の説明を表示しています。
Generates complete reference-grounded single-drug adverse-effect network-pharmacology research designs from a user-provided drug, adverse event, and desired evidence depth. Always use this skill when a user wants to design, plan, or upgrade a conventional network-pharmacology study centered on one fixed drug and one fixed adverse-effect endpoint, using drug-target prediction, adverse-event target collection, overlap analysis, PPI hub prioritization, enrichment interpretation, molecular docking, and optional orthogonal transcriptomic or literature validation. Covers five study patterns (canonical hub-first, cardiotoxicity or electrophysiology-oriented, immune-inflammatory adverse effect, organ-toxicity pathway context, translational validation) and always outputs four workload configs (Lite / Standard / Advanced / Publication+) with a recommended primary plan, dependency/evidence map, step-by-step workflow, figure plan, validation strategy, minimal executable version, publication upgrade path, verified-reference pack, and self-critical risk review.
日本語の概要は準備中です。原文の説明を表示しています。
Designs a translational blueprint for moving a biomedical finding toward diagnosis, prognosis, treatment response prediction, patient stratification, or therapeutic development, with explicit translational milestones, validation thresholds, and feasibility-sensitive route framing.
日本語の概要は準備中です。原文の説明を表示しています。
Designs studies for predicting treatment response or resistance in biomedical and clinical research. Always use this skill when the user needs a treatment-response or resistance prediction study blueprint rather than a prognostic biomarker protocol, diagnostic test design, causal treatment-effect estimation, or a completed manuscript. Focus on responder definition, treatment context, baseline comparability, feature integration strategy, model development logic, validation architecture, and interpretation boundaries. Do not invent response rates, cohort size, assay readiness, regimen uniformity, literature support, or validation access.
日本語の概要は準備中です。原文の説明を表示しています。
Finds translational opportunities that connect basic-research discoveries to clinically meaningful use cases such as diagnosis, stratification, prognosis, treatment response prediction, monitoring, or therapeutic development. Use this skill when a user wants to turn a mechanism finding, pathway signal, cellular phenotype, experimental observation, or omics discovery into a stronger translational research direction. Always separate mechanistic relevance from translational usability, and never present a basic finding as clinically actionable unless the evidence supports that level.
日本語の概要は準備中です。原文の説明を表示しています。
Use when assessing how well a survival model's predicted probabilities agree with observed outcomes by fitting a Cox model and generating bootstrap calibration curves at one or more prediction horizons from a clinical CSV file. NOT for: nomogram construction, univariate Cox screening, ROC analysis, or decision-curve analysis.
日本語の概要は準備中です。原文の説明を表示しています。
Use when evaluating the clinical utility of a binary prediction model from a single clinical CSV file by fitting a logistic decision-curve model, plotting decision and clinical-impact curves, and exporting summary outputs. NOT for: survival calibration, ROC-only discrimination analysis, nomogram construction, or time-to-event outcomes.
日本語の概要は準備中です。原文の説明を表示しています。
Selecting MPC prediction horizon and cost matrices for web handling.
日本語の概要は準備中です。原文の説明を表示しています。